Update shared on 27 Nov 2025
Fair value Increased 14%Analysts have raised their price target for Insight Molecular Diagnostics from $6.13 to $7.00 per share, citing stronger expected revenue growth and improving profit margins in their updated forecasts.
What's in the News
- Insight Molecular Diagnostics published results showing their GraftAssure assay enabled long-term non-immunosuppressed kidney transplant survival with no rejection, following CD19 CAR-T therapy in a complex patient case (study published in the American Journal of Transplantation).
- The company launched GraftAssureIQ for research use in summer 2024 and is developing GraftAssureDx as an in vitro diagnostic test kit, aiming to expand hospital access to transplant rejection testing.
- Insight Molecular Diagnostics is actively enrolling patients in a clinical trial for GraftAssureDx, now with participation from 10 leading transplant centers. The company is aiming for FDA authorization (clinical trial listing).
- A new multi-center patient registry targeting 5,000 enrollees over three years will collect real-world evidence on the GraftAssure kidney transplant rejection assay and its clinical utility in high-risk patients.
- In May 2025, Medicare increased reimbursement for GraftAssureCore to $2,753 per result. This reflects recognition of its value in the $1 billion market for transplant rejection testing.
Valuation Changes
- Consensus Analyst Price Target has increased from $6.13 to $7.00 per share. This reflects a higher fair value assessment.
- Discount Rate has risen slightly from 7.01% to 7.05%. This indicates a modest change in risk or return expectations.
- Revenue Growth forecasts have climbed significantly, from 35.1% to 41.0%.
- Net Profit Margin is projected to improve, rising from 14.4% to 16.0%.
- Future Price-to-Earnings (P/E) ratio has dropped from 174.4x to 121.6x. This suggests greater earnings potential relative to share price.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.